← All candidates
104 insider filings on record.
104 filings on record.
ADPTAdaptive Biotechnologies Corp
NasdaqGS · Healthcare · $4.25B
$26.68
+7.67% · Sep 15
104 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 55 sells
▸ hover a marker for the filing · drag to zoom · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$4.25B
Float
125.5M
79% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
13.8
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
99 more transactions on Pro →Context
Wall St
$20.57 avg target
-22.9% vs today · 7 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q1 '26−$0.13 act+$0.03
Q4 '25−$0.09 act+$0.09
Q3 '25$0.06 act+$0.20
Q2 '25−$0.17 act+$0.07
Coverage
BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT)Insider Monkey · 06-27Adaptive Biotechnologies plans separation of immune medicine platformReuters · 06-15What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?Motley Fool · 06-14Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?Zacks · 06-12
The file stays open
104 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice